Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | HCK | P08631 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.48 |
| ▸ | PRKDC | P78527 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 3/20 | 0.48 |
| ▸ | CHUK | O15111 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14555393 | 0.85 | IKBKB (0.46) | KDREPHB4PIK3CDABL1EGFR | |
| SCHEMBL20371563 | 0.82 | PIK3CD (0.46) | CYP17A1KDREPHB4PIK3CDABL1 | |
| SCHEMBL26462963 | 0.75 | PTGES2 (0.68) | IKBKBCHUKCA1CA2CA9 | |
| SCHEMBL30494473 | 0.75 | PTGES2 (0.68) | IKBKBCHUKCA1CA2CA9 | |
| SCHEMBL1270834 | 0.75 | KDM4E (0.64) | KDM4EKDRABL1EGFRSRC | |
| SCHEMBL28032548 | 0.72 | CA2 (0.73) | CA1CA2CA9CA4CA12 | |
| SCHEMBL4733938 | 0.72 | CA2 (0.64) | IKBKBCA1CA2CA9CA4 | |
| SCHEMBL13562424 | 0.72 | MAOA (0.50) | IKBKBCHUKCA1CA2CA9 | |
| SCHEMBL14075569 | 0.71 | CA9 (0.70) | IKBKBCHUKCA1CA2CA9 | |
| SCHEMBL21074248 | 0.71 | CDK8 (0.53) | KDREPHB4PIK3CDABL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161304-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2025-05-22 | — | — | US | disclosed |
| US-11491153-B2 | Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2022-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161304-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | BTK, SYK, LCK | KDM4E 515/4885CYP17A1 3863/4885KDR 1059/4885 |
| US-11491153-B2 | Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity | BTK, SYK, LCK | KDM4E 515/4885CYP17A1 3863/4885KDR 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.